Trial Profile
COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Zorecimeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms HERALD
- Sponsors CureVac
- 20 Jun 2022 Status changed from active, no longer recruiting to completed.
- 01 Mar 2022 Results published in The Lancet Infectious Diseases
- 18 Feb 2022 Number of treatment arms increased from 4 to 5, the trial will shift from randomized observer-blinded to an open-label design, accordingly patients will be enrolled in the 5th arm.